Cardiovascular Uncertainty Accompanies Canagliflozin To Advisory Panel

Janssen’s diabetes therapy also will undergo discussions about renal and bone fracture risks during a Jan. 10 meeting of FDA’s Endocrinologic and Metabolic Drugs Advisory Committee.